DPP4 as a Potential Candidate in Cardiovascular Disease
DOI: https://doi.org/10.2147/JIR.S380285
IF: 4.5
2022-09-17
Journal of Inflammation Research
Abstract:Si-Yu Chen, 1, &ast Xiang-Quan Kong, 1, 2, &ast Ke-Fan Zhang, 3, &ast Shuai Luo, 1 Feng Wang, 1 Jun-Jie Zhang 1, 2 1 Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China; 2 Department of Cardiology, Nanjing Heart Centre, Nanjing, People's Republic of China; 3 Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun-Jie Zhang, Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, No. 68 Changle Road, Nanjing, 210006, People's Republic of China, Tel/Fax +86-25-52208048, Email The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy. Keywords: DPP4, DDP4 inhibitor, GLP-1, inflammation, cardiovascular disease Cardiovascular disease is a major cause of human death worldwide, claiming estimated 17.9 million lives each year. It mostly occurs in the middle-aged and old people over 50 years old, with high morbidity, high disability rate and high mortality rate. Cardiovascular disease is often caused by a combination of risk factors, such as smoking, unhealthy diet, obesity, alcohol consumption, diabetes, hyperlipidemia, and hypertension. According to studies, improving diet, exercising, quitting smoking, and limiting alcohol consumption could prevent up to 90% of cardiovascular disease. Furthermore, targeted drug therapy to relieve symptoms in patients with hypertension, hyperlipidemia, and diabetes may also improve the progression and prognosis of cardiovascular disease. 1–3 Dipeptidyl peptidase 4, an enzyme in human body, is essential for glucose metabolism. However, recent studies found that DPP4 is widely expressed in the vascular system, including endothelial cells, macrophages, cardiomyocytes, smooth muscle cells, valve interstitial cells and other cell types, indicating that it may participate in the occurrence and progression of cardiovascular diseases. At present, DPP4 inhibitor, as a new hypoglycemic drug, is mainly used in the treatment of patients with diabetes. 4 Five recently completed large clinical trials have demonstrated the cardiovascular safety of DPP4 inhibitor, without showing benefits on major cardiovascular adverse events (MACE). 5–9 Surprisingly, more and more studies found that DPP4 inhibitor also shows protective effects on a variety of cardiovascular diseases, such as hypertension, calcified aortic valve disease, coronary atherosclerosis and heart failure. 10–12 In this review, we discuss the clinical trials of DPP4 inhibitors and elucidate the potential mechanisms by which it may improve cardiovascular disease. Dipeptidyl peptidase 4 (DPP4), also known as T cell surface antigen CD26, is a ubiquitous enzyme in human. It is widely expressed in a variety of tissues (lung, brain, pancreas, kidney, blood vessels, prostate, uterus, thymus, lymph nodes and spleen) and many cells (epithelial cells, inner skin cells, immune cells), especially highly expressed in kidney and small intestine. 13 DPP4 is a serine membrane anchored exopeptidase, belonging to DPP (dipeptidyl peptidase) family. It is a transmembrane glycoprotein composed of 766 amino acids with a relative molecular weight of 110kDa. Its basic structure mainly includes: intracellular N-terminal region, transmembrane region and extracellular region. The extracellular part consists of a flexible rod, a glycosylation rich region (binding region with anti-CD26 antibody, adenosine deaminase (ADA) and caveolin-1), a cysteine rich region (binding region with collagen and fibronectin) and a catalytic region composed of the catalytic triad Ser 630 , As -Abstract Truncated-
immunology